Cannabis for the Treatment of Fibromyalgia: A Systematic Review

Strand, Natalie; Maloney, Jillian; Kraus, Molly B; Wie, Christopher; Turkiewicz, Michal; Gomez, Diego A.; Adeleye, Olufunmilola; Harbell, Monica W.

doi:10.3390/biomedicines11061621

Cited by 11 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was found a potential role for cannabinoids in reducing pain and improving measures of quality of life (QoL) in FM, but the results were largely varying across studies and further researches are needed to strength-en this low-quality evidence. However, the review reported no severe adverse events associated with this treatment (25). A recent prospective cohort study investigated the potential role of cannabis treatment (20 grams per month for 6 months, administered by smoking, vaporizing or ingestion) in a cohort of 30 women suffering from FM; it showed improvements in general QoL, physical and psychological domain after starting cannabinoid treatment (26).…”

Section: Pharmacological Therapymentioning

confidence: 99%

Fibromyalgia: one year in review 2024

Di Carlo,

Bianchi,

Salaffi

et al. 2024

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

Fibromyalgia (FM) remains a condition with a pathogenesis that is not completely understood, affecting a significant portion of the global population. This article summarises the main advances in FM during the last year. Even in 2023, research on FM was notably active. From a clinimetric perspective, studies have been conducted to evaluate the possibilities of interchanging the primary indices of disease severity, primarily for studies with substantial case numbers. Regarding FM pathogenesis, ongoing research focuses on small fiber neuropathy: some studies have documented its association with central sensitisation, while others have revealed distinct sensory profiles in patients with FM and small fiber neuropathy compared to those solely with small fiber neuropathy. Dorsal root ganglia seem to play a crucial role in the pathogenesis of FM as they host satellite glial cells, which are targeted by pain-driving immunoglobulin G. These antibodies have been identified in a subset of patients exhibiting high symptom severity. An important study conducted on animal models confirmed the role of neuroinflammation at the level of dorsal root ganglia, in this case mediated by polymorphonuclear neutrophils. Mounting evidence underscores the link between COVID-19 and the persistence of FM symptoms after recovery. In identifying potential biomarkers aiding FM diagnosis, research has also concentrated on studying the expression of specific circulating microRNAs. Recent discoveries have unveiled novel therapeutic strategies for FM, especially focused in non-pharmacological interventions. This includes a focus on non-invasive brain stimulation and exercise programs, all directed towards relieving symptoms and improving functionality in individuals affected by the condition.

show abstract

Section: Pharmacological Therapymentioning

confidence: 99%

Fibromyalgia: one year in review 2024

Di Carlo,

Bianchi,

Salaffi

et al. 2024

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

show abstract

“…Cannabinoids are also being investigated for their potential analgesic and antiinflammatory properties [105]. Some studies suggest that cannabinoids may offer pain relief and improve sleep in individuals with fibromyalgia [106].…”

Section: Emerging Treatments and Researchmentioning

confidence: 99%

Unraveling the Complex Web of Fibromyalgia: A Narrative Review

Al Sharie,

Varga,

Al-Husinat

et al. 2024

Medicina

View full text Add to dashboard Cite

Fibromyalgia is a complex and often misunderstood chronic pain disorder. It is characterized by widespread musculoskeletal pain, fatigue, and heightened sensitivity, and has evolved in diagnostic criteria and understanding over the years. Initially met with skepticism, fibromyalgia is now recognized as a global health concern affecting millions of people, with a prevalence transcending demographic boundaries. The clinical features and diagnosis of fibromyalgia encompass a range of symptoms beyond pain, including sleep disturbances and cognitive difficulties. This study emphasizes the importance of a comprehensive evaluation for accurate diagnosis, considering the shift from tender point reliance to a more holistic approach. Etiology and pathophysiology involve genetic predisposition, neurotransmitter dysregulation, central sensitization, and immune system involvement. Risk factors such as gender, age, family history, and comorbid conditions contribute to susceptibility. The impact on quality of life is profound, affecting physical and social aspects, often accompanied by mood disorders. Management approaches include pharmacological interventions, non-pharmacological therapies, lifestyle modifications, and alternative treatments. This study also delves into emerging research, exploring advances in neurobiological understanding, brain imaging, genetic markers, glutamate modulation, cannabinoids, gut microbiome, and digital health tools for fibromyalgia management. Overall, this study provides a nuanced and up-to-date overview of the complexities surrounding fibromyalgia, aiming to enhance understanding and support for individuals grappling with this challenging condition.

show abstract